Recent developments in age-related macular degeneration: a review

Waseem M Al-Zamil
Sanaa A Yassin
Department of Ophthalmology, Imam Abdulrahman Bin Faisal University, Al-Khobar, Saudi Arabia

Introduction

Age-related macular degeneration (AMD) is an acquired disease of the macula characterized by progressive visual impairment because of late-onset neurodegeneration of the photoreceptor–retinal pigment epithelial complex. AMD is a major cause of central visual loss in the developed world affecting 10% of people older than 65 years and more than 25% of people older than 75 years. In the US alone, ~2 million individuals have advanced AMD and >8 million individuals have an intermediate form of the disease. These numbers are expected to rise by 50% in 2020. In Saudi Arabia, AMD represents 3.3% of the major causes of blindness in individuals older than 50 years.

Human retinal pigment epithelium (RPE) is a non-dividing cell, which has several functions essential for the maintenance of photoreceptor cells. RPE undergoes various changes during aging, leading to the emergence of a clinically detectable focal yellow accumulation of extracellular, polymorphous material, called drusen, at the interface between the RPE and the inner collagenous zone of Bruch’s membrane. The presence of drusen within the macula is the hallmark sign of AMD. However, individuals with small drusen in the absence of other ocular abnormalities are at a decreased risk to progress to the more severe forms of the disease. A widely variable clinical presentation related to drusen characteristics and pigmentary disturbances, such as presentation related to drusen characteristics and pigmentary disturbances, such as...
hypopigmentation and hyperpigmentation, can be found in individuals with AMD. Various pathologies, including focal detachment of the RPE, outer retinal atrophy, and new blood vessel growth between Bruch’s membrane and the retina, can progress into either geographic atrophy (GA) or choroidal neovascularization (CNV) AMD, which are also known as dry or wet AMD, respectively.

The aim of this review was to recapitulate the extensive work conducted over the last 3 decades in the clinical and pathological aspects of AMD, diagnostic tools, and therapeutic modalities presently available or underway for both atrophic and wet forms of the disease. An online review of the database PubMed was performed, searching for the key words: age-related macular degeneration, risk factors, VEGF, prevention, genetics, management, and phrases in combination. Some literature was derived from the reference lists of identified publications. Additionally literature search of the Clinical Trials (https://ClinicalTrials.gov) was performed using “age-related macular degeneration” as keyword. The search was limited to articles published since 1980 to date.

Pathophysiology
The exact pathophysiology of AMD is not fully understood; however, findings from ongoing studies are expanding our knowledge of the disease and the underlying mechanism. It is believed that the pathogenesis of AMD is the result of a complex multifactorial interaction between metabolic, functional, genetic, and environmental factors. With aging, intracellular residual bodies containing lipofuscin accumulate in RPE cells. RPE cells express such materials that would normally be eliminated by the choriocapillaris; however, as RPE dysfunction progresses, it results in alterations in the permeability of Bruch’s membrane, which leads to an accumulation of extruded material (drusen) between the two layers. The appearance of drusen may either be found with or is proceeded by a thickening of the collagenous layers of Bruch’s membrane, a degeneration of elastin and collagen within the membrane, and its calcification. Furthermore, it has been observed that the choriocapillaris thins in patients with AMD, which may contribute to the decline in the removal of extracellular material that results in drusen formation.

Twin studies have demonstrated that family history is an established risk factor for AMD. One study recently reported that drusen formation may stimulate an inflammatory cascade that has a role in AMD progression. Another study found evidence that polymorphisms in genes that encode complement factors, which have an important role in the immune system, can affect AMD risk either by increasing the risk for or by protecting against development of the disease. Evidence of associations between increased risk of AMD and complement factor H (CFH) on chromosome 1 and pleckstrin homology domain containing A1 (PLEKH1) and the hypothetical gene LOC387715 on chromosome 10 has been documented. In contrast, another study found protective effects of genetic polymorphisms in complement factor B (CFB), complement component 2 (C2) on chromosome 6, and specific haplotypes in CFH that demonstrated decreased risk of AMD.

CFH suppresses complement pathway; hence, in the presence of abnormal CFH activity, the complement cascade is activated with a consequent downstream inflammatory response to subretinal tissues. Inflammatory components from the cascade pathway have been identified within drusen, and additionally, environmental factors such as smoking can decrease CFH levels, which may account for smokers having a significantly increased risk of developing AMD compared to nonsmokers. Furthermore, complement pathway activation could be inhibited because of the protective effects conferred by polymorphisms in CFB and C2, thereby limiting the degree of chronic inflammation. Additional evidence suggests that choroidal C-reactive protein-specific deposition contributes to AMD pathogenesis in individuals with homozygous CFH.

Drusen formation signals RPE dysfunction, which promotes RPE loss with further progression that results in photoreceptor death. As previously described, RPE degeneration consequently leads to dysfunction of Bruch’s membrane. Progressive damage to Bruch’s membrane with the upregulation of vascular endothelial growth factor (VEGF) promotes the outgrowth of abnormal choroidal vessels underneath the RPE and, subsequently, under the retina. Initially, these abnormal vessels present with subretinal extravasations that may hemorrhage before they regress and form a disciform scar. Thus, the visual outcome of end-stage wet AMD is the permanent loss of central vision.

Several studies have investigated the molecular pathway that underlies GA and vision loss. This pathway implies that RPE death consequently leads to photoreceptor loss, which progressively results in visual loss over time. Low levels of the ribonucleic acid (RNA)-cleaving enzyme, DICER1, in RPE cells were observed in patients with dry AMD. It was reported that decreased levels of DICER1 lead to a decreased rate in the breakdown of RNA-Alu molecules, which are noncoding sequences of RNA. The overabundance of cytoplasmic RNA-Alu activates inflammatory proteins such as NLRP3 in the inflammasome, which results in the
activation of a cascade of molecular reactions that result in RPE cell loss. Furthermore, mitochondrial dysfunction has been associated with the development of dry AMD. The mitochondrial dysmorphology observed in the RPE in individuals with AMD was consistent with severe dysfunction.

### Risk factors

#### Age

The development of advanced AMD has multifactorial risk factors, such as increasing age, ethnicity, and genetics. Age is the strongest predictor of AMD. Although infrequent in people younger than 50 years, the risk of acquiring AMD increases more than threefold in patients older than 75 years compared to patients between 65 and 74 years of age. In the US, AMD is found in 30% of individuals older than 85 years.

#### Family history and genetics

AMD is most frequently found in Caucasians, followed by Hispanics and Asians with the lowest rate reported in African Americans. There is an increased risk in individuals with a positive family history of AMD, which is typically multifactorial in nature. Siblings of an affected individual have a threefold to sixfold higher risk than those of the general population.

To date, 34 genetic loci including 52 gene variants have been identified that have been linked to AMD. Using genome-wide screening approaches, several sets of gene variants have been identified in different chromosomes, including chromosomes 1, 6, and 10. These culprit genes play a role in controlling immune response, inflammatory processes, and retina homeostasis, and the extent of dysfunction of these reactions in individuals with AMD is attributed to variations found in these loci. The most investigated candidate genes are *CFH* on chromosome 1 at 1q31.3; high-temperature requirement serine peptidase 1 (*HTRA1*; also known as age-related maculopathy [ARM] susceptibility 2 [*ARMS2*]) on chromosome 10 at 10q26, and *CFB/C2* on chromosome 6 at 6p21.3. Other genetic variants putatively related to AMD include a polymorphism in lipase C hepatic type (*LIPC*), which is involved in high-density lipoprotein cholesterol metabolism; the single-nucleotide polymorphism (SNP) rs3775291 in toll-like receptor 3 (*TLR3*); and the tissue inhibitor of metalloproteinase 3 (*TIMP3*).

The contribution and role of genetic predisposition extend beyond increased susceptibility of an individual developing AMD and may also affect treatment response. Smailhodzic et al demonstrated a cumulative effect of high-risk alleles in *CFH, ARMS2*, and *VEGFA* that were associated with a younger age of onset and inadequate response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents in individuals with AMD. Medina et al also found that in individuals with a homozygous CC group, variants of the *CFH* gene polymorphism T1277C were associated with delayed functional and limited morphological response to the initial intravitreal injection of Avastin (bevacizumab) in wet AMD. Therefore, further pharmacogenomic studies may aid in developing a rational guide to treatment regimens and to optimize treatment response tailored to an individual’s genetic background.

#### Lifestyle, diet, and nutrition

Smoking is the main influential modifiable risk factor, and patients should be encouraged at each visit to refrain from smoking to prevent further visual loss. Smokers for >40 years are two to four times more likely to develop AMD than nonsmokers of the same age. The ALIENOR study from France showed that high pulse pressure was associated with an increased risk of late-stage AMD, whereas systolic or diastolic blood pressure or the use of antihypertensive medications was not significantly associated with an increased risk of either early- or late-stage AMD.

A high intake of certain fats, such as saturated fats, trans fats, and omega-6 fatty acids, has been associated with a twofold increase in the prevalence of AMD, whereas monounsaturated fats were potentially protective. There is conflicting evidence concerning the role of sunlight exposure in AMD occurrence. In a study that compared sun exposure of individuals with end-stage AMD to unaffected spouses, researchers found no evidence of an association; however, other studies have shown that high-energy visible light may contribute to AMD. Furthermore, data from several large population-based studies have indicated that there may be a gender effect with women at a higher risk to develop AMD compared to men.

It has been investigated whether dietary antioxidants, such as vitamins C and E, carotenoids (eg, lutein and zeaxanthin), and zinc, are additional risk factors for AMD; however, data from observational studies revealed insufficient evidence supporting a role.

#### Aspirin use

There is inconsistent evidence linking aspirin use and AMD. The Beaver Dam Eye Study demonstrated that the incidence of late-stage AMD in patients who used aspirin at least twice weekly for 10 years was higher compared to those who
did not use aspirin, whereas a different study reported that aspirin conferred a potentially protective effect against developing the disease. A meta-analysis of 10 studies, including >171,000 patients, concluded that aspirin use was not a risk factor for AMD. Based on the available information on aspirin use in patients with AMD, the current preferred practice is to continue aspirin therapy prescribed by physicians.

Other risk factors

Combined analysis of longitudinal data from two large population-based cohorts suggests an increased risk of developing late-stage AMD, particularly neovascular AMD in older individuals who undergo cataract surgery.

Other proposed risk factors for AMD include abdominal obesity, especially among men; hyperlipidemia; hyperopia; light iris color; cardiovascular disease; hormonal status; alcohol use; vitamin B and D status; and elevated C-reactive protein.

A systematic review including 18 prospective and cross-sectional studies and six case–control studies involving 113,780 individuals identified age (>60 years), smoking, previous cataract surgery, and a family history of AMD as strong risk factors for AMD, whereas increased body mass index, previous cardiovascular disease, hypertension, and higher plasma fibrinogen were found to be moderate risk factors.

Table 1 summarizes the risk factors associated with AMD.

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Strength and consistency of association</th>
</tr>
</thead>
<tbody>
<tr>
<td>Older age</td>
<td>Strong and consistent</td>
</tr>
<tr>
<td>Cigarette smoking</td>
<td></td>
</tr>
<tr>
<td>Previous cataract surgery</td>
<td></td>
</tr>
<tr>
<td>Family history of AMD</td>
<td></td>
</tr>
<tr>
<td>Higher body mass index</td>
<td>Moderate and consistent</td>
</tr>
<tr>
<td>History of cardiovascular disease</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
</tr>
<tr>
<td>Higher plasma fibrinogen</td>
<td>Weak and inconsistent</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
</tr>
<tr>
<td>Iris color</td>
<td></td>
</tr>
<tr>
<td>History of cerebrovascular disease</td>
<td></td>
</tr>
<tr>
<td>Serum total cholesterol</td>
<td></td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td></td>
</tr>
<tr>
<td>Triglyceride levels</td>
<td></td>
</tr>
</tbody>
</table>

Table 1 Summary of risk factors for AMD

Abbreviations: AMD, age-related macular degeneration; HDL, high-density lipoprotein.

Classification and severity grading

Various classification systems are used to delineate and characterize AMD for both clinical and research purposes. Currently, there is no universally accepted consensus on specific definitions, although conventionally, AMD has two main types of macular degeneration known as dry and wet AMD. Dry AMD, which is also known as the nonexudative form, is the most common type, comprising ~90% of all diagnosed cases. GA is the advanced stage of dry AMD. Wet AMD is also known as the exudative form, and although less common than dry AMD, it is associated with a more rapid progression to advanced vision loss. The main manifestations of wet AMD are CNV and pigment epithelial detachment (PED). Approximately 10%–20% of patients with nonexudative AMD may develop the wet form, which is estimated to affect 1.75 million people in the US.

The development of standardized photographic retinal grading methods such as the Wisconsin ARM grading system was followed by the International ARM Epidemiological Study for classification and grading, which redefined the diagnostic system and led to the adoption of a stricter criterion for diagnosing AMD. The ARM grading system was characterized by minimal or moderate nonexudative age-related changes in the macula. By definition, the presence of advanced RPE atrophy (ie, GA) or CNV was essential to establish a diagnosis of nonexudative AMD or wet AMD, respectively. After applying the International Classification criteria, ARM accounted for ~85%–90% of cases with AMD representing 10%–15% of affected individuals with age-related macular changes.

The Age-Related Eye Disease Study (AREDS) defined the categories of AMD based on the presenting features of drusen, atrophy, and neovascularization (Table 2). Drusen were classified as small (<63 μm in diameter), intermediate (63–124 μm), or large (>125 μm). AREDS categories of AMD were defined as: 1) no AMD if there were fewer than five small drusen; 2) mild AMD based on the identification of multiple small drusen or at least one intermediate-sized drusen; 3) intermediate AMD classified by extensive intermediate-sized drusen, more than one large drusen, or non-central GA; and 4) advanced AMD determined by central GA or CNV causing vision loss (defined as visual acuity [VA] worse than 20/32) in one eye.

Klein et al developed a risk assessment model using data from AREDS; the model incorporated demographic, environmental, phenotypic, and genetic covariates. The model gave satisfactory results, with very good discrimination,
Recent developments in AMD

Clinical features and diagnosis

AMD is characterized by a variable presentation of clinically observable changes at the posterior pole.

Variable types, sizes, and distribution of drusen within the posterior pole with a high degree of symmetry between the two eyes of an individual are characteristics of dry AMD. Pseudodrusen are a different entity from conventional drusen. They are drusenoid deposits located in the subretinal space above the RPE. Pseudodrusen are associated with advanced AMD. They have been classified into three groups, dot, reticular, and confluent pseudodrusen, depending on different morphological appearances. It was found that the prevalence of GA was associated with the presence of ribbon-dominant (confluent)-type pseudodrusen, large soft drusen, and female gender. Pigmentary disturbances are a frequent finding in AMD that can be in the form of either focal hyperpigmentation or hypopigmentation. Progressive well-demarcated atrophic patches of the RPE may appear in the perifoveal area. Over time, these atrophic patches enlarge and may coalesce, resulting in GA. Wet AMD may present with drusen, PED, intraretinal hemorrhages, and CNV, which appears as a well-demarcated graying area of the retina.

There are different methods for diagnosis, including fundus imaging and optical coherence tomography (OCT). Digital fundus photography is an effective approach to...
document clinical findings. However, there are a few difficulties that hinder precision of color photograph measurements, such as image quality, resolution, noise, and dynamic, as well as the sensitivity of the camera, media clarity, and fundus pigmentation. Foveal involvement is also difficult to determine. Fundus autofluorescence (FAF) imaging depends on the stimulated emission of light from molecules in the RPE, mainly lipofuscin. FAF imaging is a helpful tool for evaluating and monitoring the topographic structure and health of the RPE because the localized deposition of lipofuscin in RPE cells results in increased autofluorescence, whereas in contrast, a decrease or absence of RPE lipofuscin will result in a decreased FAF signal.

In case of GA, a well-circumscribed dark area typically appears in FAF images that clearly delineates atrophy of the RPE. Increased autofluorescence surrounding the GA area has been considered a risk factor for the progression of AMD. The multicenter Fundus Autofluorescence in Age-related Macular Degeneration (FAM) study using a confocal scanning laser ophthalmoscopy classified patterns of abnormal FAF in the junctional zone of GA in patients with AMD into five different patterns as follows: none, focal increased, banded, patchy, and diffuse. The progression rate of GA was highest in eyes with the diffuse trickling pattern followed by the banded pattern in a study on 54 eyes. A hyperpigmented area in the fundus can either show as decreased FAF intensities because of absorption by melanin granules or as increased FAF signal, which is believed to arise from melanolipofuscin. Similarly, variable increased or decreased intensities of FAF can be observed in non-RPE-related changes, such as subpigment epithelial or subneurosensory detachments, areas with extracellular fluid exudation or hemorrhage with subsequent biosynthesis of fluorophores that possess autofluorescent properties.

Spectral-domain optical coherence tomography (SD-OCT) has provided an improved understanding of the microstructural changes related to AMD. For example, drusen may appear as elevations at the level of the RPE. In GA, OCT demonstrated loss of the RPE layer and photoreceptor bands within the atrophic lesion. In addition, OCT is used to determine subretinal or intraretinal blood or fluid. Fluid appears as black gaps or elevations and is indicative of wet AMD. OCT is often used when fluorescein angiography (FA) is equivocal and is used to monitor treatment responses. The technology of OCT has progressed rapidly since its first introduction to ophthalmology in 1995. Improved axial resolution and increased scanning speed have facilitated the introduction of new OCT techniques, which can more effectively visualize the posterior segment. En-face OCT is one such visualization approach that has significantly benefited from technical advancements. En-face OCT in current systems is based on software reconstruction of OCT images.

Nunes et al used en-face OCT to study the progression of GA at the inner/outer segment junction of 30 patients with AMD. Interestingly, they found outer retinal disruption that extended beyond the borders of GA, which are visualized as focal hyporereflective areas on en-face OCT, predicted GA progression for 1 year in 43.3% of eyes in their patient cohort. Another novel technique OCT angiography (OCT-A) is an in vivo noninvasive imaging of blood vessels with a high resolution in three dimensions, thus enabling a qualitative and quantitative analysis of characteristics of normal and pathological blood vessels at different layers of the retina and choroid. OCT-A may have applications in both neovascular and non-neovascular AMD. In neovascular AMD, OCT-A can be used to monitor treatment response over time, while in non-neovascular AMD, it is useful to study the choriocapillaris and other vascular structures believed to be important in the pathogenesis of the disease.

FA reveals drusen that bind fluorescein and hyperfluorescence in the late stage of angiography; however, fluorescein uptake depends on the components found in drusen that can vary from being hydrophobic to hydrophilic (Figure 1). Consequently, only 50% of clinically identifiable drusen will stain with fluorescein. Large drusen tend to stain with fluorescein more frequently than smaller drusen. During the transit phase of FA, areas of GA appear as well-demarcated patches of hyperfluorescence surrounded by a rim of blocked fluorescence with visualization of the choroidal vessels passing through the region. In the late phase of FA, some staining may persist. The gold standard for confirming diagnosis whenever CNV is suspected is FA. In addition, FA may assist in determining the pattern (classic or occult), borders, composition, and location of the neovascular complex as well as guide treatment with laser or intravitreal injections.

In the early phases of FA, CNV presents as a hyperfluorescent lesion that enlarges in size and intensity in late phases as the fluorescein leaks from the neovascular membranes. The two major angiographic patterns are classic and occult forms of CNV. Differences between the two patterns are thought to arise from the location of the neovascular membrane. In classic lesions, CNV penetrates the RPE and grows in front of the RPE, whereas occult lesions are sub-RPE. As shown in Figure 2, classic CNV is characterized by well-circumscribed lesions with early hyperfluorescence and progressive leakage in later frames. A concomitant pooling of fluorescein in the
subretinal space can also be observed. Occult CNV is categorized as an ill-defined leakage from an undetermined source. Occult CNV is also presumed when a fibrovascular PED is suspected because these detachments are accompanied with an irregular RPE elevation and a stippled hyperfluorescent pattern with or without leakage or pooling.\textsuperscript{84}

The value of indocyanine green (ICG) angiography in assessing and treating AMD has been debated. Nevertheless, ICG is useful in assessing specific forms of AMD, such as occult CNV, which is poorly defined, and lesions like retinal angiomatous proliferation or idiopathic polypoidal choroidal vasculopathy.\textsuperscript{86}

Although their specific role in clinical practice is not distinctly determined, other tests such as microperimetry can be used to quantify retinal sensitivity and fixation in AMD.\textsuperscript{87,88}
Prophylaxis and treatment of dry AMD

Current management of GA in AMD basically depends on documentation, observation, and surveillance for early recognition of any changes in visual function and detection of CNV at a treatable stage. Home monitoring for changes in the central visual field is usually advised using an Amsler grid to detect the presence of metamorphopsia or scotoma in individuals with dry AMD, although the sensitivity of Amsler charts in revealing macular disease can be suboptimal.

The identification of modifiable risk factors and the development of future preventive treatments are crucial because there is currently no available treatment of dry AMD and population aging will result in a major upsurge in AMD burden on both families and socioeconomically. Thus, intense efforts have been made to identify possible therapeutic targets to reduce disease progression. Tobacco smoking is consistently associated with AMD, and because it is a modifiable risk factor, a primary therapeutic recommendation should advocate the significance of smoking cessation. In addition, the preventive role of antioxidant supplements was evaluated in several studies. Oxidative damage from various sources, such as light exposure, inflammation, and oxidative stress, to the retina has been strongly linked with AMD. Although results from initial epidemiological studies indicated an association, later studies were inconclusive. The AREDS study was designed to determine whether antioxidant supplementation could have protective effects against AMD. AREDS was a multicenter, randomized, double-masked, clinical trial that enrolled 3,640 participants and was stratified into four categories of severity. The study demonstrated that a daily dose of vitamin C (500 mg), vitamin E (400 IU), β-carotene (15 mg), zinc oxide (80 mg), and cupric oxide (2 mg) significantly reduced the odds of developing advanced AMD in individuals with high-risk characteristics. The greatest risk reduction (34% odds reduction) was seen in participants from categories 3 and 4, who received both antioxidants and zinc (odds ratio [OR] =0.66; P=0.001), compared to other categories in the treatment arm.

A second AREDS study (AREDS2) was started in 2006 to evaluate the role of oral supplementation with high doses of lutein, zeaxanthin, and omega-3 fatty acids (docosahexaenoic acid [DHA] and its precursor eicosapentaenoic acid [EPA]). A second objective of the study was to assess the effects of eliminating beta-carotene and reducing the zinc dose from the original AREDS formula. After a median 5-year follow-up, there was no convincing support toward including DHA/EPA or lutein/zeaxanthin to the AREDS formula, although subgroup analysis indicated that substitution of beta-carotene with lutein and zeaxanthin showed a slightly decreased risk of progression (hazard ratio =0.82; P=0.02). However, participants who were former smokers and took the revised formula with beta-carotene were more prone to lung cancer compared to those whose formula did not include beta-carotene (2.0% vs 0.9%, respectively; P=0.04). The final recommendation from AREDS2 was to substitute beta-carotene with lutein/zeaxanthin in the updated formula.

Dry AMD has no approved treatment, which is driving efforts toward understanding the pathophysiology of the disease for the development of rationale treatments. Several innovative treatments for dry AMD are in progress. Because inflammation and polymorphisms in genes involved in the complement pathway have been consistently linked to AMD pathogenesis, several trials were performed to evaluate the safety, tolerability, and response of different complement inhibitors to treat dry AMD. The 18-month Phase II MAHALO study assessed the efficacy of monthly intravitreal injections of lampalizumab in halting the progression of GA in patients with bilateral disease. Lampalizumab (anti-factor D Fab) is a humanized monoclonal antibody (Fab fragment), which is a selective inhibitor of complement factor D (CFD). Using autofluorescence and color fundus photographs, it was found that patients had a 20% reduction in mean change from baseline in the GA area at month 18. Remarkably, in a subset of complement factor I-positive patients, intravitreal administration of lampalizumab was associated with a significant 44% reduction in the GA area progression at month 18 compared to sham treatment (P<0.005). Lampalizumab is under further evaluation in two large, prospective, Phase III, randomized, double-masked clinical trials, CHROMA and SPECTRI. Currently, lampalizumab is the most promising potential therapeutic agent for dry AMD that may be commercially available as early as 2019.

There is evidence that tetracyclines can target the low-grade inflammation caused by aberrant complement pathway activation, which is believed to underlie the pathogenesis of dry AMD, and may also slow the progression of GA. Doxycycline is a broad-spectrum antibiotic at a dose of 100 mg a day; however, at a lower dosage (20–40 mg/day), it acts as an anti-inflammatory. Low-dose oral doxycycline is currently approved for treating the inflammatory lesions of rosacea and is under investigation in a randomized, double-masked, placebo-controlled study (TOGA) to determine its efficacy and safety in slowing the progression of GA in patients with AMD.
Table 3  Emerging treatments targeting advanced AMD are being tested actively in clinical trials

<table>
<thead>
<tr>
<th>Agent</th>
<th>Targeted pathology</th>
<th>Route of administration</th>
<th>Mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lampalizumab&lt;sup&gt;89&lt;/sup&gt;</td>
<td>GA</td>
<td>Intravitreal</td>
<td>Anti-factor D Fab</td>
</tr>
<tr>
<td>Oracea&lt;sup&gt;94&lt;/sup&gt;</td>
<td>GA</td>
<td>Oral</td>
<td>Antibiotic–anti-inflammatory</td>
</tr>
<tr>
<td>MTP-131 (Ocuvia)&lt;sup&gt;107&lt;/sup&gt;</td>
<td>GA</td>
<td>Topical</td>
<td>Mitochondrial protective compound</td>
</tr>
<tr>
<td>MA09-hRPE&lt;sup&gt;110&lt;/sup&gt;</td>
<td>GA</td>
<td>Subretinal injection</td>
<td>Human umbilical tissue-derived cells</td>
</tr>
<tr>
<td>Brimonidine tartrate implant&lt;sup&gt;113&lt;/sup&gt;</td>
<td>GA</td>
<td>Intravitreal implant</td>
<td>Alpha-2-antagonist</td>
</tr>
<tr>
<td>Eculizumab&lt;sup&gt;116&lt;/sup&gt;</td>
<td>GA</td>
<td>Intravitreal</td>
<td>mAb against complement factor C5</td>
</tr>
<tr>
<td>E10030&lt;sup&gt;117,118&lt;/sup&gt;</td>
<td>Neovascular AMD</td>
<td>Intravitreal</td>
<td>Anti-PDG Pegylated aptamer</td>
</tr>
<tr>
<td>Proton radiation&lt;sup&gt;119&lt;/sup&gt;</td>
<td>Neovascular AMD</td>
<td>External radiation</td>
<td>Radiation: proton radiation</td>
</tr>
<tr>
<td>Abicipar pegol&lt;sup&gt;120&lt;/sup&gt;</td>
<td>Neovascular AMD</td>
<td>Intravitreal injection</td>
<td>Anti-VEGF</td>
</tr>
<tr>
<td>RTH258&lt;sup&gt;121&lt;/sup&gt;</td>
<td>Neovascular AMD</td>
<td>Intravitreal injection</td>
<td>Anti-VEGF</td>
</tr>
</tbody>
</table>

Abbreviations: AMD, age-related macular degeneration; GA, geographic atrophy; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor.

Statins are lipid-lowering anti-inflammatory agents with pleiotropic actions. There is emerging genetic and pathological evidence from a cross-sectional study that included 5,604 participants in the National Health and Nutrition Examination Survey from 2005 to 2008, ≥40 years of age, who were confirmed to diagnosis of AMD, the use of statins, and comorbidities and health-related behaviors such as smoking. The study suggests a possible role for statins in delaying the progression of AMD and its prevention in individuals at the age of 68 years or older,<sup>105</sup> however, additional studies are needed to fully evaluate their therapeutic importance.

A novel mitochondrial protective compound, MTP-131 (Ocuvia), is a topical ophthalmological investigational drug under development to treat dry AMD. Preliminary testing of MTP-131 in cell culture and in a mouse model of AMD was performed, and the results indicated that the investigational drug was highly effective in several experimental models.<sup>106</sup> Currently, a Phase I/II open-label dose-escalation clinical study on topical MTP-131 is carried on to determine its safety and tolerability in patients with diabetic macular edema and dry AMD.<sup>107</sup>

Rapamycin (Sirolimus) is an inhibitor of the mammalian target of rapamycin complex (mTOR), which is a pleiotropic protein kinase involved in regulating organismal growth and homeostasis. Sirolimus is clinically administered as an immunosuppressive agent following organ transplantation for its ability to suppress T-cell and B-cell proliferation and antibody production.<sup>108</sup> However, intravitreal or subconjunctival (440 µg/every 3 months) administration of sirolimus in six eyes or 11 eyes, respectively, showed no effect on VA, GA size, or GA progression in patients with dry AMD.<sup>108,109</sup>

Stem-cell therapy is under investigation as a potential cell-replacement approach for damaged and lost photoreceptors and RPE cells in GA lesions. A prospective study of nine patients with atrophic AMD (median age of 77 years) showed that subretinal transplantation of human embryonic stem-cell derived retinal epithelial cells improved VA at 12 months in the treated eye compared to that in the untreated eye.<sup>110</sup> Although the procedure was well tolerated and patients were followed for up to 3 years, these findings only support proof of concept and are too preliminary to suggest its use in treatment. Table 3 lists the emerging treatments targeting advanced AMD.

Other promising concepts of therapeutic approaches in the pipeline are to target inflammasomes,<sup>111</sup> visual cycle modulators,<sup>112,113</sup> glatiramer acetate (suppressor of T cells and downregulates inflammatory cytokines),<sup>114</sup> and neuroprotection.<sup>113,115</sup> As part of regular patient care and to ensure continued quality of life, individuals with poor vision should be supported by low vision aids as needed.

**Treatment of wet AMD**

Management of wet AMD has undergone significant advances in recent years. So far, none of the used treatments could certainly cure the disease or reverse its course. Macular photocoagulation studies (1970s) showed the effectiveness and efficacy of laser photocoagulation in the treatment of wet AMD. Remarkable visual outcome was described in extrafoveal lesions,<sup>116,117</sup> while parafoveal lesions showed less favorable results.<sup>118,119</sup>

Laser therapy was not considered as an ideal procedure for treating subfoveal lesions despite reported benefits.<sup>120,121</sup> Currently, the adoption of laser photocoagulation in the treatment of wet AMD is hampered by several issues, including a high recurrence rate; a risk of producing vision loss, especially with subfoveal membranes; and a limited visual improvement potential. In the era of anti-VEGF therapies, the role of direct photocoagulation as a major treatment approach for wet AMD is waning. However, if used, this treatment should be limited to treat very small lesions outside the central macula.
Photodynamic therapy (PDT) was introduced in the late 1990s. The photosensitizer verteporfin is administered intravenously at a dose of 6 mg/m² of body surface area and is activated by photons with a low-energy visible red laser (689 nm) using a specific type of contact lens. The activated dye forms reactive-free radicals that damage the vascular endothelium and induce occlusion of new vessels. Verteporfin is an approved photosensitizer by the US Food and Drug Administration (FDA) for ophthalmic use. The selectivity of the photosensitizer to the CNV, which retains the dye more avidly than normal vessels, allows directed targeting at the lesion without damaging surrounding tissues. In a Phase III trial, 609 participants with subfoveal neovascular AMD were randomized to PDT or placebo; it demonstrated that more eyes treated with PDT were spared from moderate vision loss than those treated with placebo (loss of <15 letters of VA at 12 months; 61% vs 46%, respectively; \( P<0.001 \)). In subgroup analyses, the VA benefit (<15 letters lost) found in the PDT arm was robustly demonstrated in eyes with predominantly classic lesions on FA compared to the placebo arm (67% vs 39%, respectively; \( P<0.001 \)). The effects were maintained at 2 and 3 years of follow-up. The use of PDT became more prevalent worldwide for a brief period. However, because of inadequate and unpredictable effects of PDT on CNV, which have led to a large number of recurrences and the need for retreatments, and with the rise of other treatment options, the use of PDT in treating wet AMD has declined. In the current anti-VEGF treatment era, PDT alone is infrequently used in practice. However, its use is usually considered in combination with an anti-VEGF agent and/or steroid administration as a second line of therapy in eyes that are not responding to monotherapy.

The first anti-VEGF agent that received FDA approval for the treatment of wet AMD was in 2004. Macugen (pegaptanib) was considered a unique therapy in its objective and mechanism of action. It is a RNA aptamer that specifically binds to the VEGF-165 isoform. In the VISION studies, participants with different types of subfoveal CNV were randomized to receive 0.3, 1.0, or 3.0 mg of intravitreal pegaptanib injections or sham treatment every 6 weeks over a period of 48 weeks. At 48 weeks, patients receiving 0.3 mg pegaptanib were more likely to have maintained their VA or to have gained acuity compared to those who received sham injection (33% vs 23%, respectively; \( P=0.003 \)). However, since this study, newer and more effective anti-VEGF agents have widely substituted pegaptanib.

Lucentis (ranibizumab) is a recombinant humanized IgG1 monoclonal Fab fragment created from the same parent antibody as bevacizumab. It inhibits all biologically active VEGF-A isoforms. In 2006, ranibizumab was approved by the FDA for the treatment of wet AMD after its effectiveness was determined in the ANCHOR and MARINA trials. In the ANCHOR study, 423 patients with predominantly classic CNV were randomized 1:1:1 to verteporfin PDT plus monthly sham intravitreal injection or to sham verteporfin PDT plus monthly intravitreal ranibizumab (0.3 or 0.5 mg) injection. The role of ranibizumab in the treatment of predominantly classic CNV was highlighted and showed improved VA (35.7%–40.3%) in patients at 1 year with a low rate of severe ocular adverse events. The MARINA trial investigated the role of intravitreal administration of ranibizumab in the management of 716 patients with minimally classic or occult CNV for 2 years and demonstrated that ranibizumab prevented loss <15 letters in 94.5% of patients and improved mean VA in 24.8%–33.8% of patients.

A recombinant humanized monoclonal IgG1, bevacizumab, is an anti-VEGF-A antibody originally developed for systemic administration as a chemotherapeutic agent, receiving FDA approval for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma multiforme, renal cell carcinoma, cervical cancer, ovarian cancer, fallopian tube cancer, and peritoneal cancer. However, because of its low cost, its off-label use became prevalent as an alternative intravitreal anti-VEGF for the treatment of several retinal diseases. The National Eye Institute funded the randomized Comparison of AMD Treatments Trials (CATT) to compare the effectiveness of bevacizumab versus ranibizumab for neovascular AMD. A total of 1,208 participants with neovascular AMD were randomized to ranibizumab or bevacizumab on either a monthly or as-needed schedule. Both bevacizumab and ranibizumab had similar efficacies on VA over 24 months, and there were no differences between the two drugs in the frequency of death or arteriothrombotic events. The remaining issue was the unresolved debate of higher rates of serious adverse events with bevacizumab because of a lack of specificity to conditions associated with inhibition of VEGF. The Inhibition of VEGF in Age-related Choroidal Neovascularization (IVAN) study was a second head-to-head trial with an analogous protocol, enrollment of 610 patients, and its primary outcome of best VA at 2 years again supported the fact that bevacizumab was not inferior to ranibizumab. A meta-analysis evaluating the results of the data from both the CATT and the IVAN trials convincingly demonstrated that bevacizumab was not inferior to ranibizumab in best-corrected VA in patients with wet AMD. Since these studies, two additional
randomized trials evaluated both drugs and demonstrated non-inferiority or equivalent efficacy of bevacizumab compared to ranibizumab.

Eylea (aflibercept) is the latest approved anti-VEGF agent, which is a VEGF-A receptor decoy with a high affinity to all VEGF-A and VEGF-B isoforms and to placentation growth factor. It is a recombinant fusion protein consisting of the ligand-binding elements of human VEGF receptor 1 and receptor 2 fused to the human immunoglobulin G1 fragment crystallizable (Fc) region. Aflibercept received FDA approval in 2011 and promptly gained popularity competing with other anti-VEGF agents on the market. The VIEW trials included two parallel trials that randomly assigned 2,419 participants to 0.5 mg aflibercept monthly, 2.0 mg aflibercept monthly, 2.0 mg aflibercept every 2 months after three initial monthly doses, or 0.5 mg ranibizumab monthly. All the aflibercept groups, including the bimonthly group, were shown to be non-inferior to monthly ranibizumab. The sustained effects of aflibercept can be accounted for its higher binding affinity.

Basically, four dosing regimens of anti-VEGF treatment in neovascular AMD are in clinical use, a fixed regimen using monthly or bimonthly injections, a pro re nata (PRN) strategy, a treat-and-extend regimen, and an observe-and-plan regimen. Generally, initial treatment with intravitreal anti-VEGF agents is given at a fixed monthly interval. However, once disease stability is achieved, the follow-up and treatment plan are tailored according to clinical status and the judgment of the treating physician, in an attempt to reduce the treatment frequency and inconvenience on patients’ life. In the PRN strategy, the retreatment is an individualized regimen based on monthly evaluation visits, to detect early recurrence. This regimen allows for a reduced number of injections; however, the tremendous burden of monthly visit on patients and the health care system is unresolved. The treat-and-extend regimen is based on progressive lengthening of the intervals between the visit-injection dates. Each visit is combined with an injection, and the visit result determines the subsequent interval to the next visit-injection date. This approach is becoming increasingly popular. It allowed for reducing the number of injections and simultaneously the number of visits with lower costs compared with fixed, monthly retreatment, along with maintaining an overall good VA outcome. Treat-and-extend regimen showed several advantages over the PRN regimen, reducing the number of visits along with the number of injections, ranging from 7.6 to 8.4 in the first year. The observe-and-plan regimen is based on an initial three loading doses, followed by a monthly observation; once signs of recurrence appeared on SD-OCT, the ideal treatment interval is considered to be 2 weeks shorter than the elapsed interval. Subsequently, this interval is then applied for several fixed injections without intermittent evaluation. Monitoring visits following each series of injections aim to tune the interval in the subsequent injection series. This emerging regimen achieved a favorable functional outcome with fewer clinic visits.

Several cost-effective analyses studies compared the less frequent injections of aflibercept with ranibizumab and bevacizumab. All studies agreed that irrespective of the treatment protocol used, bevacizumab is cost-efficient in a comparison with aflibercept, which in turn is more cost-efficient than ranibizumab.

Currently, the three widely used intravitreal anti-VEGF agents, ranibizumab, bevacizumab, and aflibercept, have proven to be highly effective treatments that can effectively prevent legal blindness in patients with wet AMD. However, there is a compelling need for a long-lasting therapy solution for patients with AMD because of the cost of the drugs, patient access and adherence to treatment, and the increasing burden of frequent office visits to receive injections, especially as the population ages. Considerable research efforts continue toward developing extended-release therapeutics and intraocular drug-delivery devices. Table 4 summarizes the important results of some of the studies done on anti-VEGF for neovascular AMD.

An adjuvant treatment used in combination with VEGF inhibition is transpupillary thermotherapy (TTT). TTT delivers a waveform near the infrared spectrum through the pupil to the target tissue. At low doses (136 mW/mm), the surrounding neurosensory retina is not damaged. In a trial using sham procedure as a control, 100 patients with wet AMD were randomized to receive low-dose TTT or sham TTT every 3 months for 2 years. Patients in the TTT group required fewer treatments with ranibizumab compared to those in the sham group (mean 8.0 vs 6.3 over 2 years, respectively). There were no differences in the corrected VA or the lesion area between the two groups.

PDT in combination with anti-VEGF and steroid administration is currently reserved as a second-line therapy for patients not responding to monotherapy with an anti-VEGF agent. Combined therapy using ranibizumab and verteporfin PDT was more effective than PDT alone, and the combination of PDT with bevacizumab has also been effective in many cases. Reports on whether intravitreal administration of triamcinolone in combination with PDT provides added benefits are conflicting.
Table 4 Summary of the important results of some of the studies done on anti-VEGF for neovascular AMD

<table>
<thead>
<tr>
<th>Study</th>
<th>Drug</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>MARINA</td>
<td>Ranibizumab</td>
<td>• Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean VA, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) CNV secondary to AMD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Most important predictors of VA outcomes were (in decreasing order of importance) baseline VA score, CNV lesion size, and age</td>
</tr>
<tr>
<td>ANCHOR</td>
<td>Ranibizumab</td>
<td>• In this 2-year study, ranibizumab provided greater clinical benefit than verteporfin PDT in patients with AMD with new-onset, predominantly classic CNV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Rates of serious adverse events were low</td>
</tr>
<tr>
<td>HORIZON</td>
<td>Ranibizumab</td>
<td>• Multiple ranibizum injections were well tolerated for ≥4 years. With less frequent follow-up leading to less treatment, there was an incremental decline in the VA gains achieved with monthly treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• There were no differences in-between drugs in rates of death or arteriothrombotic events</td>
</tr>
<tr>
<td>CATT</td>
<td>Ranibizumab,</td>
<td>• Ranibizumab and bevacizumab had similar effects on VA over a 2-year period</td>
</tr>
<tr>
<td></td>
<td>bevacizumab</td>
<td>• Treatment as needed resulted in less gain in VA</td>
</tr>
<tr>
<td>VIEW I/VIEW II</td>
<td>Aflibercept,</td>
<td>• Visual improvement achieved at week 52 was largely maintained through week 96 with both aflibercept and ranibizumab injections</td>
</tr>
<tr>
<td></td>
<td>ranibizumab</td>
<td>• The original 2q8 aflibercept group achieved efficacy results that were similar to ranibizumab, with an average of 5.3 fewer injections over the 96-week period</td>
</tr>
<tr>
<td>SEVEN-UP</td>
<td>Ranibizumab</td>
<td>• Approximately 7 years after ranibizumab therapy in the ANCHOR or MARINA trials, one-third of patients demonstrated good visual outcomes, whereas another one-third had poor outcomes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Compared with baseline, almost half of eyes were stable, whereas one-third declined by ≥15 letters. Even at this late stage in the therapeutic course, exudative AMD patients remain at risk for substantial visual decline</td>
</tr>
</tbody>
</table>

Abbreviations: VEGF, vascular endothelial growth factor; AMD, age-related macular degeneration; VA, visual acuity; CNV, choroidal neovascularization; PDT, photodynamic therapy.

Pegpleranib (E10030, Fovista; Ophthotech, New York, NY, USA) is a new drug, which is an inhibitor of platelet-derived growth factor (anti-PDGF) aptamer that binds to PDGF. Pegpleranib promotes decrease in the pericyte density in the neovascular membrane, making it more receptive to anti-VEGF agents, and therefore, it is administered intravitreally in combination with anti-VEGF. Pegpleranib has shown promising early results in Phase I and Phase II trials. The pegpleranib Phase III program consists of three clinical trials to evaluate the safety and efficacy of pegpleranib in combination with multiple anti-VEGF agents (ranibizumab, bevacizumab, and aflibercept) for the treatment of wet AMD. However, the two Phase III studies comparing pegpleranib and ranibizumab combination treatment over standard-of-care ranibizumab monotherapy were terminated. The outcomes of these studies did not meet the primary end point, which was an additional letter gain in best-corrected VA, to indicate superiority of combination therapy with pegpleranib and ranibizumab over ranibizumab monotherapy. Although it has been announced that patient recruitment in a Phase III trial of pegpleranib in combination with aflibercept or bevacizumab for the treatment of wet AMD has been completed, data have not yet been provided.

Other treatment modalities under investigation include the role of adjunctive treatments alongside anti-VEGF by stereotactic radiotherapy (ie, use of a low-voltage external beam) to reduce the frequency of intravitreal injections needed while maintaining VA. Ranjbar et al demonstrated that the mean number of intravitreal injections was reduced by almost 50% during the 12 months after stereotactic radiotherapy compared to the number required the year before and that VA increased by one line (logMAR). Other promising therapeutic approaches are modulators of angiogenesis. Home-monitoring devices for the early detection of disease progression and development of CNV may increase the likelihood of an earlier initiation of treatment, which may further improve clinical outcomes. Findings from a previous study have indicated that early detection of AMD can be achieved with devices that measure defective dark adaptation.

Two main surgical procedures have been attempted for AMD with limited success, namely, submacular surgery and macular translocation surgery. Submacular surgery involves removal of abnormal subretinal neovascularization and any large submacular hemorrhages, if present. Clinical trials were unsatisfactory, showing a lack of benefit to the patients and high rates of complications. However, there may be a role for submacular surgery in treating AMD, but only for patients with extensive peripapillary membranes. Macular translocation surgery is experimental and involves...
relocating the macula to a less affected area of the retina in patients with subfoveal CNV.\textsuperscript{185,186} The advent of effective pharmacological therapy has limited the use of this surgical modality to either patients with large submacular hemorrhages or patients unresponsive to anti-VEGF treatment.\textsuperscript{187} The surgical risks are serious, including retinal detachment, proliferative vitreoretinopathy, and diplopia.\textsuperscript{183}

**Conclusion**

Available evidence indicates that risk profiling of AMD is largely based on advanced age of the patient, lifestyle decisions (smoking and diet), family history of AMD, and signs of soft drusen and pigmentary abnormalities. The identification of major susceptibility genes over the last decade has opened new insights toward understanding the role of complement-mediated inflammation and oxidative stress in disease pathogenesis and, consequently, identified underlying mechanistic pathways for the development of novel therapeutic approaches. Treatment of atrophic AMD is largely close observation coupled with nutritional supplements, such as zinc and antioxidants. However, treatment of wet AMD is based on targeting choroidal neovascular membranes. Advances in anti-VEGF agents have transformed the approach in treating patients with wet AMD. These advances have resulted in more favorable outcomes for a previously blinding disease. Substantial research efforts continue in the identification and evaluation of new therapeutic modalities for both forms of this disease.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Clinical Interventions in Aging 2017:12

Recent developments in AMD


Clinical Interventions in Aging 2017:12
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                     Dovepress                                                                                                                                                                                                                   Dovepress                                                                                                                                                                                                                   1329


